Beta lamellar blocking peptide for preventing and/or curing Alzheimer's disease

A residue and sequence technology, applied in the field of prevention and/or treatment of Alzheimer's disease, can solve the heavy burden on patients' families and society, and affect the quality of life of patients and their family members, etc.

Active Publication Date: 2009-09-16
TIANJIN MEDICAL UNIV +1
View PDF5 Cites 6 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

This disease seriously affects the quality of life of patients and their family members, and also imposes a heavy burden on patients' families and society

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Beta lamellar blocking peptide for preventing and/or curing Alzheimer's disease
  • Beta lamellar blocking peptide for preventing and/or curing Alzheimer's disease
  • Beta lamellar blocking peptide for preventing and/or curing Alzheimer's disease

Examples

Experimental program
Comparison scheme
Effect test

preparation example Construction

[0069] Preparation of the polypeptide of the present invention

[0070] The polypeptides of the present invention can be prepared by any method known to those skilled in the art for preparing polypeptides.

[0071] Polypeptides of the invention can be synthesized using chemical synthesis. Polypeptide synthesis can be performed in solution or using solid-phase synthesis. The solid-phase synthesis method of polypeptide includes Fmoc solid-phase synthesis method and tBoc solid-phase synthesis method. The method of artificially synthesizing polypeptides is generally synthesized from the C-terminus (carboxyl-terminus) to the N-terminus (amino-terminus).

[0072] In one embodiment of the present invention, the polypeptide of the present invention is synthesized by Fmoc solid-phase synthesis method, and purified by HPLC. Fig. 1 shows in an exemplary manner the main steps of synthesizing and purifying a polypeptide H101 of the present invention and the detection results of the pr...

Embodiment 1

[0076] Embodiment 1: the preparation of polypeptide of the present invention

[0077] In this example, a polypeptide H101 of the present invention was first synthesized using the Fmoc / tBu solid-phase polypeptide synthesis method, and the sequence of the polypeptide is:

[0078] His-Lys-Gln-Leu-Val-Phe-Phe-Glu-Glu-Asp (SEQ ID NO: 1).

[0079] The raw materials used in the polypeptide synthesis method of this example are: Fmoc-Asp(OtBu)-Wang Resin(0.37mmol / g), Fmoc-Val-OH, Fmoc-Glu(OtBu)-OH, Fmoc-His(trt)- OH, Fmoc-Gln(trt)-OH, Fmoc-Leu-OH, Fmoc-Lys(Boc)-OH and Fmoc-Phe-OH.

[0080] The main steps of the polypeptide synthesis and purification method used in this example are as follows: Figure 1A shown.

[0081] Figure 1A The formulation of the TFA reagent used in the shown protocol is: [TFA:H 2 O: ethanedithiol: phenol, mixed with a volume ratio of 92.5:2.5:2.5:2.5].

[0082] The prepared peptide crude product is purified by HPLC, so that the purity of the peptide finall...

Embodiment 2

[0088] Embodiment 2: The effect of the polypeptide of the present invention on β-amyloid protein

[0089] Materials and Methods

[0090] 1. Drugs and reagents: Aβ 1-42(purity>98%), vitamin E, Thioflavin T (Thioflavin T, ThT), thiazolyl blue (MTT), dimethyl sulfoxide (DMSO), were all purchased from Sigma Company of the United States; MEM medium, fetal bovine serum ( FBS), trypsin (trypsin) are all purchased from U.S. Gibco-BRL company; Several polypeptides H101, H102 and H103 of the present invention are prepared by the method described in Example 1; Methods A pentapeptide Leu-Pro-Phe-Phe-Asp was synthesized, which had the same sequence as the β-sheet blocking peptide iAbeta5 invented by Soto-Jara et al., and was named L5 in the present invention. The L5 peptide will be used as a control in this example and the following examples. The above peptides were all synthesized by Shanghai Jill Biotechnology Co., Ltd., and purified by high performance liquid chromatography (High p...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
diameteraaaaaaaaaa
Login to view more

Abstract

The invention relates to a Beta lamellar blocking peptide which can be used for preventing and/or curing Alzheimer's disease and the application of the polypeptide used for preventing and/or curing Alzheimer's disease.

Description

technical field [0001] The present invention relates to polypeptides and uses thereof, more specifically, the present invention relates to a class of beta-sheet blocking peptides that can be used to prevent and / or treat Alzheimer's disease, and the polypeptides are used to prevent and / or treat Alzheimer's disease Uses for Alzheimer's disease. Background technique [0002] Alzheimer's disease (AD), also known as senile dementia, is a neurodegenerative disease with insidious onset and progressive course. The typical clinical features are comprehensive cognitive impairment and personality changes, manifested as Early short-term memory impairment, followed by persistent mental decline, aphasia, loss of judgment and reasoning ability, and movement disorders. This disease seriously affects the quality of life of patients and their family members, and also imposes a heavy burden on patients' families and society. [0003] With the acceleration of population aging process, senile ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): C07K7/06A61K38/08A61P25/28
Inventor 徐淑梅周根发王威
Owner TIANJIN MEDICAL UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap